Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 41 (2), 73-82

Cancer Prevention With Green Tea and Its Principal Constituent, EGCG: From Early Investigations to Current Focus on Human Cancer Stem Cells


Cancer Prevention With Green Tea and Its Principal Constituent, EGCG: From Early Investigations to Current Focus on Human Cancer Stem Cells

Hirota Fujiki et al. Mol Cells.


Cancer preventive activities of green tea and its main constituent, (-)-epigallocatechin gallate (EGCG) have been extensively studied by scientists all over the world. Since 1983, we have studied the cancer chemopreventive effects of EGCG as well as green tea extract and underlying molecular mechanisms. The first part of this review summarizes ground-breaking topics with EGCG and green tea extract: 1) Delayed cancer onset as revealed by a 10-year prospective cohort study, 2) Prevention of colorectal adenoma recurrence by a double-blind randomized clinical phase II trial, 3) Inhibition of metastasis of B16 melanoma cells to the lungs of mice, 4) Increase in the average value of Young's moduli, i.e., cell stiffness, for human lung cancer cell lines and inhibition of cell motility and 5) Synergistic enhancement of anticancer activity against human cancer cell lines with the combination of EGCG and anticancer compounds. In the second part, we became interested in cancer stem cells (CSCs). 1) Cancer stem cells in mouse skin carcinogenesis by way of introduction, after which we discuss two subjects from our review on human CSCs reported by other investigators gathered from a search of PubMed, 2) Expression of stemness markers of human CSCs compared with their parental cells, and 3) EGCG decreases or increases the expression of mRNA and protein in human CSCs. On this point, EGCG inhibited self-renewal and expression of pluripotency-maintaining transcription factors in human CSCs. Human CSCs are thus a target for cancer prevention and treatment with EGCG and green tea catechins.

Keywords: AFM; Nanog; Oct4; Sox2; stemness.


Fig. 1
Fig. 1. Primary, secondary, and tertiary cancer prevention in humans
Fig. 2
Fig. 2. Schematic illustration of mechanisms of EGCG in relation to “Sealing effects of EGCG”

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles


    1. Affara N.I., Trempus C.S., Schanbacher B.L., Pei P., Mallery S.R., Bauer J.A., Robertson F.M. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multistage mouse skin carcinogenesis. Anticancer Res. 2006;26:2805–2820. - PubMed
    1. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., Sotiropoulou P.A., Loges S., Lapouge G., Candi A., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 2011;478:399–403. - PubMed
    1. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66:1234–1240. - PubMed
    1. Boumahdi S., Driessens G., Lapouge G., Rorive S., Nassar D., Le Mercier M., Delatte B., Caauwe A., Lenglez S., Nkusi E., et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511:246–250. - PubMed
    1. Boutwell R.K. The role of the induction of ornithine decarboxylase in tumor promotion. In: Hiatt H.H., Watson J.D., Winsten J.A., editors. Origins of Human Cancer. New York: Cold Spring Harbor Laboratory; 1977. pp. 773–783.